Biophytis SA filings document its foreign private issuer reporting for an ADR linked to a clinical-stage biotechnology company focused on age-related diseases. The company files Form 6-K reports that furnish press releases, interim financial reporting, meeting results, and other information distributed by the French issuer.
The filing record addresses BIO101 program disclosures, sarcopenia and obesity development updates, strategic and co-development agreements, capital increases, warrants, convertible debt repayment, bond financing amendments, and shareholder governance matters. These disclosures also show how the company reports financing activity and program spending alongside its Euronext Growth Paris ordinary-share listing and OTC ADS program.
Biophytis S.A. will hold its Ordinary and Extraordinary General Meeting on November 12, 2026, where shareholders will vote on resolutions continuing prior authorizations and providing the Board with financing flexibility. A proposed share consolidation would allow the Board, if approved, to decide later whether to consolidate up to 100 existing shares into one new share; the 2025 meeting authorized a maximum of 400 existing shares for one new share. The resolutions do not themselves approve an immediate capital increase.
Biophytis says that, following the capital increase completed in September, initiation of the Phase 2 OBA obesity study is funded, with recruitment of the first patient expected in the first quarter of 2027. OBA will evaluate BIO101 as an adjunct to GLP-1-based treatments and study a possible rebound following their discontinuation. The company is preparing the SARA-31 Phase 3 program through its Hong Kong joint venture. Expected next steps include an intellectual-property contribution, a license agreement and an initial $3 million financing tranche after necessary administrative approvals, as part of a commitment that could reach $20 million over three years.
Biophytis SA filed a new Rule 506(b) notice of exempt offering, reporting $2,598,526 USD sold and $0 USD remaining to be sold. The listed securities are equity, rights to acquire another security, and securities acquired upon exercise of those rights; the first sale is dated September 15, 2026. Maxim Group, LLC appears in the sales compensation section, and reported finders' fees are $0 USD.
Biophytis SA (BPTSY) completed a capital increase raising €5.3 million in gross proceeds, including €4.75 million in cash and €0.55 million via rollover of Hexagon debt, through the issuance of 101,923,092 new shares and 127,403,865 share subscription warrants.
Each warrant allows subscription to one new share at €0.06 within 60 months, and the new shares were priced at €0.052, a 24.1% discount to the 10‑day volume‑weighted average price. This Placement is primarily intended to finance the Phase 2 OBA obesity trial of BIO101 and extends the company’s cash runway to at least the first quarter of 2028.
Following the offering, Biophytis has 350,132,497 shares outstanding and a cash and cash equivalents position of €8.9 million477,536,362, implying significant dilution for non‑participating shareholders, illustrated by a reduction of a 1% pre‑deal stake to 0.71% post‑offering and 0.57% if all warrants are exercised.
Biophytis SA (BPTSY) reported that it has submitted to Brazilian regulator ANVISA an amendment to the protocol of its phase 2 OBA clinical study in obesity. The amendment adds an evaluation of BIO101’s potential to limit weight regain after discontinuation of semaglutide, a GLP-1 receptor agonist. Submission of the same protocol to the U.S. FDA is expected in the coming days, with plans to start the study in the first quarter of 2027 and report results in the first half of 2028.
The OBA study will enroll 164 obese and overweight patients treated with semaglutide across the United States, Europe, and Brazil. The primary endpoint remains improvement in lower-limb muscle strength via knee extension test, while the amended protocol adds a 12-week follow-up after a 21-week semaglutide treatment period to characterize weight regain and assess BIO101’s role in maintaining benefits. The study is conducted under a licensing agreement with Blanver, under which Biophytis may receive up to €108 million in upfront and milestone payments plus double-digit royalties, and also benefits from non-dilutive support from EMBRAPII.
Biophytis SA (BPTSY) reports that recent financing actions have strengthened its cash position and extended its cash runway into the first quarter of 2027. Gross cash inflows of €3.7 million came mainly from the exercise of 2026 share warrants and drawdowns on a Hexagon bond facility, leading to cash of €3.0 million as of August 31, 2026 (pro forma, unaudited).
The company reduced financial debt by more than 30% via €1.4 million of debt-to-equity conversions, bringing financial debt down from €4.27 million at December 31, 2025 to €2.90 million at August 31, 2026. These transactions resulted in the issuance of tens of millions of new shares and an estimated total of about 240 million shares outstanding.
Biophytis plans to use available cash and existing financing instruments to finalize preparations for its Phase 2 OBA obesity study, expected to start in the first quarter of 2027, and to support a Hong Kong joint venture preparing a Phase 3 SARA sarcopenia study in China while funding operations into the same period.
Biophytis SA (BPTSY) outlines progress on its Hong Kong joint venture, Biophytis Biopharmaceutical Holding LTD, created to develop and commercialize BIO101 for sarcopenia in China, Japan, and South Korea. Partners are finalizing initial contributions, expected to be completed by end of September 2026, subject to administrative approvals.
Biophytis will contribute BIO101-related patents in China, Japan, and South Korea and sign a license through which the joint venture will pay single-digit royalties on future sales. Asian partners will fund the joint venture with up to $20 million over three years, including $10 million in the first year and an initial $3 million tranche concurrent with IP contribution and licensing.
Biophytis and its founders will hold 29% of the joint venture and the Asian consortium 71%, with a five-member board (three Biophytis-side, two partners). Funding is expected to cover most costs of the SARA-31 Phase 3 trial in sarcopenia, enrolling 942 patients across China, Japan, and Europe, targeting conditional marketing authorizations in Asia and the EU.
Biophytis SA reports that Brazil’s health authority ANVISA has approved initiation of the Phase 2 OBA clinical trial of BIO101 in obesity, adding Brazil to previously secured approvals in the United States and Europe. This confirms the company’s capacity to run a multi-regional development program.
The OBA study will enroll 164 obese and overweight patients already treated with GLP-1 therapies to assess whether BIO101 can preserve muscle strength, mobility, and reduce sarcopenia risk. The primary endpoint is improvement in lower-limb strength measured by the knee extension test.
The trial is part of an existing licensing agreement with Brazilian partner Blanver, under which Biophytis may receive up to 108 million euros in upfront and milestone payments, plus double-digit royalties on future net sales in Latin America. EMBRAPII is providing non-dilutive financial support, and the study is scheduled to begin in early 2027.
Biophytis SA published audited parent-company financial statements for 2025 and announced that trading in its shares on Euronext Growth Paris has resumed. The statements, prepared under French accounting rules, show a net loss of €8.2 million and negative shareholders’ equity of €8.8 million for the year.
Total financial debt and current liabilities amounted to €11.9 million as of 31 December 2025, down 5% versus 2024, mainly from a €1.7 million reduction in bond borrowings after financial restructuring. Operating expenses fell 17%, helping reduce the net loss from €9.4 million in 2024.
Cash and cash equivalents were €187 thousand at year-end. Based on refinancing completed in early 2026, current plans and the Hexagon bond facility, the company expects to finance operations only through 30 September 2026, creating significant uncertainty about its ability to continue as a going concern. The statutory auditors reported they were unable to express an unqualified opinion, citing going-concern uncertainties and the accounting treatment of certain capital transactions.
Biophytis SA reported provisional, unaudited 2025 results showing no revenue and a net loss of €7.8 million, an improvement from €9.4 million in 2024 as research, development and administrative costs declined and financial expenses fell sharply.
Cash and cash equivalents were €190 thousand as of December 31, 2025, versus €72 thousand a year earlier, while total financial debt and current liabilities stood at €12.5 million. Management states that current resources, recent refinancing and access to a Hexagon bond facility should finance operations only until September 30, 2026, creating a material uncertainty about the company’s ability to continue as a going concern.
The company highlights a memorandum of understanding with Asian partners to form a Hong Kong joint venture for BIO101 in sarcopenia, with up to US$20 million to be invested and a first US$3 million tranche expected after JV registration. Trading in Biophytis shares on Euronext Growth Paris has been suspended since June 15, 2026 due to delayed publication of 2025 audited accounts and is expected to resume once audited financial statements are released, planned by the end of July 2026.